Galera Therapeutics, Inc. GRTX
Set alert
As of Aug 3, 2:11 PM ET
- YTD
- +77,854.55%
- 1 year
- +59,037.93%
- Open
- 16.00
- Prev close
- 17.15
- Mkt cap
- 3.56B
- Vol
- 420
- Avg vol
- 84.88K
- EPS
- 0.64
- P/E
- 0.06
- Div yield
- 0.00%
More statistics
- Low
- 16.00
- High
- 17.15
- Beta
- 2.60
- Inst. own
- 0.00%
- Dividend
- 0.00
Key statistics
- Market cap
- 3.56B
- Enterprise value
- 3.56B
- Trailing P/E
- 0.06
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.68
- Beta
- 2.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -210.64%
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 14, 2026 | Mar 31, 2026 | -0.83128 | -0.01 | +0.82 | +98.80% |
| Mar 19, 2026 | Dec 31, 2025 | -60.00 | 0.66 | +60.66 | +101.10% |
| Nov 13, 2025 | Sep 30, 2025 | -58.00 | -0.01 | +57.99 | +99.98% |
| Aug 13, 2025 | Jun 30, 2025 | 165.45 | -14.00 | -179.45 | -108.46% |
| May 15, 2025 | Mar 31, 2025 | -58.89 | -0.01 | +58.88 | +99.98% |
| Mar 31, 2025 | Dec 31, 2024 | -57.06 | -0.08 | +56.98 | +99.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 29, 2023 | Citigroup | main | Neutral | Neutral |
| Aug 16, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 10, 2023 | Piper Sandler | down | Overweight | Neutral |
| Jul 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 22, 2023 | HC Wainwright & Co. | main | — | Buy |
| Feb 21, 2023 | Piper Sandler | init | — | Overweight |
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 3
- Website
- galeratx.com
News
- Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
- Galera Therapeutics (NASDAQ:GRTX) vs. Eagle Pharmaceuticals (NASDAQ:EGRX) Head to Head Review
- GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
- Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Galera Therapeutics, Inc. (OTCMKTS: GRTX)
- Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
- Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
- Critical Review: Galera Therapeutics (NASDAQ:GRTX) versus China Pharma (NYSE:CPHI)
- Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Your note
Sign in to keep a note on GRTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 6, 2026 | 8,825,540 |
| EMERALD BIOVENTURES LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 14, 2026 | 0 |
| FRIEDMAN MICHAEL R | Director | Conversion of Exercise of derivative security | Apr 6, 2026 | 0 |
| SORENSEN J. MEL | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |
| SORENSEN MELINDA | Chief Executive Officer | Sale | Nov 19, 2025 | 195,029 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ascentis Independent Advisors | 0.00% | 93 | 1.51K | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Master Investment Portfolio-Diversified Equity Master Portfolio | 0.00% | 7 | 113 | Mar 30, 2026 |